Tag: 爱地希®

In 2022, with an estimated 2.3 million new cases and nearly 700.000 deaths globally, breast cancer emerged as the most prevalent cancer after lung...

RC118, an antibody-drug conjugates or ADC being developed by RemeGen, a commercial-stage biotechnology company based in Yantai, China, has been granted two orphan drug...

Earlier this month, Remegen Biosciences, a Shandong-based biotech company operating since 2008, scored the largest ever out-license deal for a Chinese biotech company when...

Disitamab vedotin (爱地希®/Aidixi®; Previously known as RC48; Remegen Biosciences) has been granted conditional marketing approval by the National Medical Products Administration (NMPA; 国家药品监督管理局) of...